Profound Medical Corp.
PROF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.06 | -0.05 | 0.13 |
| FCF Yield | -6.44% | -7.93% | -4.74% | -2.92% |
| EV / EBITDA | -16.09 | -10.75 | -12.11 | -11.92 |
| Quality | ||||
| ROIC | -27.42% | -31.35% | -20.08% | -120.24% |
| Gross Margin | 74.32% | 73.18% | 70.70% | 68.12% |
| Cash Conversion Ratio | 1.20 | 0.88 | 0.77 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 30.70% | 20.60% | 18.68% | 15.97% |
| Free Cash Flow Growth | 32.62% | -69.86% | -46.81% | 17.35% |
| Safety | ||||
| Net Debt / EBITDA | 3.22 | 2.22 | 3.78 | 4.13 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -196.70 |
| Efficiency | ||||
| Inventory Turnover | 0.16 | 0.07 | 0.11 | 0.29 |
| Cash Conversion Cycle | 651.18 | 1,323.09 | 878.34 | 356.71 |